We have previously shown that FKBP12 associates with RyR2 in cardiac muscle and that it modulates RyR2 function differently to FKBP12.6. We now investigate how these proteins affect the single-channel behavior of RyR1 derived from rabbit skeletal muscle. Our results show that FKBP12.6 activates and FKBP12 inhibits RyR1. It is likely that both proteins compete for the same binding sites on RyR1 because channels that are preactivated by FKBP12.6 cannot be subsequently inhibited by FKBP12. We produced a mutant FKBP12 molecule (FKBP12E31Q/D32N/W59F) where the residues Glu31, Asp32, and Trp59 were converted to the corresponding residues in FKBP12.6. With respect to the functional regulation of RyR1 and RyR2, the FKBP12E31Q/D32N/W59F mutant lost all ability to behave like FKBP12 and instead behaved like FKBP12.6. FKBP12E31Q/D32N/W59F activated RyR1 but was not capable of activating RyR2. In conclusion, FKBP12.6 activates RyR1, whereas FKBP12 activates RyR2 and this selective activator phenotype is determined within the amino acid residues Glu31, Asp32, and Trp59 in FKBP12 and Gln31, Asn32, and Phe59 in FKBP12.6. The opposing but different effects of FKBP12 and FKBP12.6 on RyR1 and RyR2 channel gating provide scope for diversity of regulation in different tissues.

INTRODUCTION
FK506-binding proteins (FKBPs) bind tightly to ryanodine receptor (RyR) channels in cardiac and skeletal muscle, and evidence suggests that they play an important regulatory role that is impaired in disease, for example, in heart failure (1–4) and certain skeletal muscle disorders (5). It is reported that FKBPs provide a stabilizing effect on RyR channel function by lowering open probability (Po) and preventing subconductance state gating and that, at the cellular level, this leads to fewer leaky RyR channels and fewer aberrant Ca²⁺-release events (6–8). It is generally thought that FKBP12 stabilizes RyR1 and FKBP12.6 stabilizes RyR2 (1,9–11). This is a controversial area, however, because not all investigators agree that low Po or substate gating in RyR channels is dependent on the binding of FKBPs (12–15). Moreover, we have recently shown that FKBP12 binds with high affinity to RyR2, causing channel activation and stimulating Ca²⁺-induced Ca²⁺-release in isolated cardiac myocytes (15). We demonstrated that FKBP12.6 cannot itself lower RyR2 Po, but because it is a partial agonist of very low efficacy, it can act as an antagonist of FKBP12 and indirectly reduce RyR2 Po and sarcoplasmic reticulum (SR) Ca²⁺-release in cardiac cells. Thus, the gating of RyR2 in cardiac muscle is under the dual modulation of FKBP12 and FKBP12.6, rather than the exclusive influence of FKBP12.6. Other experiments also suggest that FKBP12 and FKBP12.6 do not selectively regulate RyR1 and RyR2, respectively. In an FKBP12 knockout mouse model, skeletal muscle function appeared normal, whereas cardiac hypertrophy and disturbances in cardiac excitation-contraction coupling were very severe (16). It has also been shown that FKBP12.6 can affect skeletal muscle function (17–19), indicating that, similar to RyR2 in cardiac muscle, RyR1 may also be subjected to dual regulation by FKBP12 and FKBP12.6. We have therefore investigated how FKBP12 and FKBP12.6 affect the single-channel behavior of RyR1 and, to understand the mechanisms underlying their functional effects, we have made direct comparisons of their effects on RyR2 gating. FKBP12 and FKBP12.6 share the same number of amino acids (108) and with 82% sequence identity have similar molecular masses (11.8 kDa, FKBP12.6; 11.9 kDa, FKBP12 (15)). X-ray crystallography highlights the close structural similarity of the two proteins, providing few clues about the residues that may be important for binding to RyR1 and RyR2 or for transducing distinct functional effects. Previous work has indicated that the residues Gln3, Arg18, and Met49 are necessary for FKBP12 binding to RyR1 (20). Likewise, mutation of Asp37 to Val or Ser is reported to enhance the affinity of FKBP12.6 for RyR2 (21,22). Although affinity is important, the particular amino acid residues important for efficacy (the ability of FKBP12/12.6 to act as agonist or antagonist of RyR1/RyR2) have not been investigated previously. By locating the steric and electrostatic differences between FKBP12 and FKBP12.6 we identified three amino acid residues that could be relevant in this respect. We generated a mutant FKBP12 molecule (FKBP12E31Q/D32N/W59F), in which these three residues were mutated to the corresponding residues found in FKBP12.6 and investigated if the mutant possessed increased or decreased ability to act as an activator (agonist) of RyR1 and/or RyR2. We find that FKBP12 is an inhibitor of RyR1 but an activator of RyR2. Conversely, FKBP12.6 is an activator of RyR1 but has barely detectable ability to activate RyR2. The triple mutant, FKBP12E31Q/D32N/W59F, lost all ability to activate RyR2 and inhibit RyR1 but instead, caused significant activation of RyR1. Thus, the ability for conferring selectivity of RyR agonist behavior is contained within a few key amino acids.

MATERIALS AND METHODS
Isolation of membrane fractions and bilayer techniques
Heavy sarcoplasmic reticulum (HSR) vesicles were obtained from sheep hearts (collected from an abattoir) or rabbit skeletal muscle, as described previously (23). SR vesicles were fused with planar phosphatidylethanolamine lipid bilayers as described (23). Incorporation of RyR always occurred in the same fixed orientation with the cis side corresponding to the cytosolic channel side and the trans side to the luminal face. The trans-chamber was held at ground and the cis-chamber clamped at potentials relative to ground. After fusion, the cis-chamber was perfused with 250 mM HEPES, 80 mM Tris, 10 mM free Ca²⁺, pH 7.2. The trans-chamber was perfused with 250 mM glutamic acid and 10 mM HEPES, pH to 7.2 with Ca(OH)₂ (free [Ca²⁺], ~50 mM). Experiments were performed at 22 ± 2°C. Free [Ca²⁺] and pH were maintained constant during experiments and were determined using a Ca²⁺ electrode (Orion 93–20, Thermo Fisher Scientific Inc., Waltham, MA) and Ross-type pH electrode (Orion 81–55, Thermo Fisher Scientific Inc., Waltham, MA) as previously described (23). FKBP12 and FKBP12.6 were added to the cis-chamber. Both proteins were stored in a buffer containing 10 mM HEPES, 50 mM NaCl, 0.5 mM DTT and volumes added to the cis-chamber were <2% of the total volume. Control experiments demonstrated that the buffer alone caused no effects on RyR function. Rapamycin treatment of the skeletal HSR membrane fraction was obtained by incubating vesicles with 20 μM rapamycin for 15 min at 36°C. Following incubation, the membrane fraction was sedimented at 180,000 × g for 15 min at room temperature. Preparation of wild-type and mutant FKBPs Human FKBP12 and rabbit FKBP12.6 were cloned, expressed, and purified as previously described (15). The preparation of FKBP12E31Q/D32N/W59F triple mutant is described in the Supporting Material. FKBP12 was also purchased from Sigma-Aldrich (Dorset, UK). Statistics Data are expressed as mean ± SE where n ≥ 4. For n = 3, SD is given. Where appropriate, Student's t-test was used to assess the difference between treatments. Where multiple treatments were compared, analysis of variance followed by a modified t-test was used to assess the difference between treatments. A p value of <0.05 was taken as significant. Materials All chemicals were obtained from VWR (Poole, UK) or Sigma-Aldrich. All solutions were prepared in MilliQ deionized water (Millipore, Harrow, UK) and those for use in bilayer experiments were filtered through a Millipore membrane filter with 0.45 μm pore diameter. RESULTS We have previously demonstrated that both FKBP12 and FKBP12.6 behave as very high affinity, partial agonists of RyR2 (15). FKBP12 activates RyR2 at low picomolar concentrations. In contrast, the stimulatory effects of FKBP12.6 on RyR2 are usually imperceptible because although FKBP12.6 can bind to RyR2, it has extremely low efficacy. The Supporting Material (Fig. S1) shows typical examples of how FKBP12 and FKBP12.6 affect RyR2 gating. To make direct comparisons, identical recording conditions were used to investigate the effects of FKBP12 and FKBP12.6 on rabbit skeletal RyR1 gating. Unexpectedly, FKBP12.6 caused an increase in RyR1 Po. This effect was irreversible on the timescale of a single-channel experiment as washout of protein from the cytosolic chamber did not lower Po (Fig. 1A). The irreversibility of the FKBP12.6 effect suggests a high affinity interaction between FKBP12.6 and RyR1 and this is confirmed by the fact that concentrations as low as 10 pM FKBP12.6 can significantly increase Po. Fig. 1B shows the mean data for different concentrations of FKBP12.6. The mean open and closed times derived from experiments where only single channels were present in the bilayer were 1.68 ± 0.35 ms and 91.2 ± 34.9 ms, respectively, before and 2.26 ± 0.27 ms and 58.4 ± 37.3 ms (SD; n = 3), respectively, after addition of 200 nM FKBP12.6 indicating that FKBP12.6 primarily increases channel opening frequency with little effect on open lifetime duration. Lifetime analysis (see Fig. S2) confirms this mechanism of action; the open lifetime distribution is not altered even at high concentrations of FKBP12.6. In contrast, FKBP12 always reduced the Po of RyR1. A typical experiment is shown in Fig. 2A with mean data shown in Fig. 2B. Washout of cytosolic solutions to remove unbound FKBP12 did not reverse the inhibition as shown in the bottom trace. In four experiments where FKBP was washed out and Po was recorded for a further 3 min, Po was 0.007 ± 0.005 before and 0.002 ± 0.001 (SE; n = 4) after washout. The diary plot of channel activity during a typical experiment is shown in Fig. 2C. This illustrates the modal gating that is characteristic of RyR channels (25,26) and the irreversibility of the effect of FKBP12. Detailed lifetime analysis was not possible because of the low number of events that occurred after addition of FKBP12. However, mean open and closed times were 2.41 ± 0.16 ms and 22.9 ± 3.94 ms (SE; n = 4), respectively, before and 2.04 ± 0.04 ms and 332 ± 142 ms (SE; n = 4), respectively, after the addition of 500 nM FKBP12 showing that the main effect of FKBP12 is to reduce channel opening frequency. It is generally assumed that FKBP12.6 is not important for RyR1 function in skeletal muscle because FKBP12.6 is present at very low levels, whereas FKBP12 is present at micromolar levels (1–3 mM) (12,27,28). The data shown in Fig. 1, however, indicates that activation of RyR1 results from a high affinity interaction with FKBP12.6 and so an important question to answer is whether FKBP12 and FKBP12.6 could compete for the same binding sites. If so, then preaddition of FKBP12.6 should prevent FKBP12 from causing the immediate inhibition of RyR1 that is shown in Fig. 2C. Fig. 3A and B confirm that this is the case. Preaddition of FKBP12.6 (200 nM) prevents FKBP12 (500 nM) from causing channel inhibition (on the timescale of a single-channel experiment). There are two further issues to consider. 1) If the affinities of FKBP12/FKBP12.6 for RyR1 are as high as Figs. 1 and 2 suggest and the dissociation of FKBPs from RyR1 is very slow, then even picomolar quantities of either isoform should prevent the binding of the other. 2) Physiological levels of FKBP12 are likely to be at least 5–10 times the levels of FKBP12.6, therefore, what happens in the competition studies if FKBP12 is present at 10 times the levels of FKBP12.6? To address these questions, we have performed experiments at 10 pM FKBP12.6 and 100 pM FKBP12 (pretreating first with 10 pM FKBP12.6 (Fig. 3C) or 100 pM FKBP12 (Fig. 3D). The experiments demonstrate pharmacological consistency; the high affinity binding and slow dissociation rate of either isoform of FKBP blocks the binding of the subsequently added isoform of FKBP.PPP1CB Proteinsupplier

To identify the amino acid residues in FKBP12 that are important for the selective ability of FKBP12 to reduce the Po of RyR1 and increase the Po of RyR2, we compared the specific amino acids of FKBP12 and FKBP12.6 that differ. Fig. 4 compares the primary sequences of FKBP12 and FKBP12.6 and their three-dimensional structures (FKBP12 purple; Protein Data Bank (PDB) 2DG3; FKBP12.6 green; PDB 1C9H) and illustrates their high structural similarity. Indeed, the root mean-squared deviation between the superimposed backbone atoms is only ~0.44 Å. On the basis of their steric and electrostatic properties, we identified three residues that could have particular relevance. Glu31 and Asp32 are negatively charged residues of FKBP12, whereas the corresponding residues in FKBP12.6 are neutral (Gln31 and Asn32). Trp59 in FKBP12 is located within the hydrophobic binding pocket for rapamycin and has a larger side chain (an indole) compared with Phe59 (a phenyl group) in FKBP12.6. The locations of these three amino acid residues in FKBP12 and the corresponding residues in FKBP12.6 are highlighted.

We produced a triple mutant of FKBP12 where these three highlighted amino acids were mutated to the corresponding residues in FKBP12.6 thus converting Glu31 to Gln, Asp32 to Asn, and Trp59 to Phe. The affinity of various mutants of FKBPs for RyR proteins have previously been investigated (20,29), although the ability to influence RyR single-channel function (efficacy) has not been studied. The FKBP12E31Q/D32N/W59F triple mutant retains affinity for RyR channels (20,29) and therefore is a molecule of choice for studying efficacy (because we must use mutant molecules that bind to RyR channels to study efficacy). We then investigated the ability of FKBP12E31Q/D32N/W59F to influence the gating of RyR1 and RyR2 under identical experimental conditions to those used with the wild-type proteins. Representative examples of the effects of FKBP12E31Q/D32N/W59F on RyR2 gating are shown in Fig. 5. FKBP12E31Q/D32N/W59F produced no observable changes in RyR2 gating even at nanomolar or micromolar concentrations. Clearly, the triple mutant protein, FKBP12E31Q/D32N/W59F, has lost the normal ability of FKBP12 to activate RyR2 and behaves instead like FKBP12.6; efficacy has been lost. When FKBP12E31Q/D32N/W59F was added to RyR1 channels, an increase in Po was observed (Fig. 6), very similar to that observed with FKBP12.6 (see Fig. 1). The representative experiment shown in Fig. 6A illustrates the increase in the frequency of channel openings that was induced by FKBP12E31Q/D32N/W59F and demonstrates that washout of the mutant protein from the cytosolic chamber could not reverse the effects of the mutant. To observe the variations in Po that occur with time, diary plots of Po against time were recorded (see Fig. 6B). The effects of a range of concentrations of FKBP12E31Q/D32N/W59F were investigated and in all cases, FKBP12E31Q/D32N/W59F activated RyR1 (Fig. 6C). It is possible that some endogenous FKBP could still be associated with the channels in the bilayer before we add exogenous FKBPs. However, because we observe reproducible effects with both FKBP12 and FKBP12.6 and at both RyR1 and RyR2, it is obvious that there are always vacant FKBP binding sites on both channels that are functionally relevant. We do not know how many molecules of FKBP12 or FKBP12.6 must bind to RyR channels to produce their effect. The irreversible nature of the binding makes this difficult to examine at the single-channel level.

Many previous reports have used drugs such as rapamycin or FK-506 to strip FKBPs from RyRs (9,11,30–33). However, even in these studies, it was not possible to be certain that all FKBP molecules were removed because Western blot was the only proof of FKBP dissociation and this is not a technique able to detect low levels of proteins. In fact, later work shows that these treatments do not achieve complete displacement of bound FKBPs (34,35). We have therefore treated SR vesicles with rapamycin (20 μM) using previously published methods (30) and performed mass spectrometry to detect the FKBPs because this is a more sensitive method of protein detection than Western blot analysis. We find that FKBP12 is still detected with high confidence (false discovery rate < 1%; Table S1) demonstrating that rapamycin treatment does not remove all FKBP proteins from rabbit skeletal SR. Western blot analysis shown in Fig. 7, A and B, shows that rapamycin is very effective at dissociating FKBPs from the SR but that there is a residual amount left which, depending on the sensitivity of the antibody, may not always be immunodetectable. In the literature, there is heavy reliance on the ability of rapamycin to dissociate FKBPs from RyR channels to infer mechanistic insight into FKBP effects on RyR function. However, such reasoning is questionable because there are reports that rapamycin may affect RyR channel behavior directly (35,36). We have therefore examined if rapamycin affects RyR1 gating by incorporating the rapamycin pretreated SR vesicles into bilayers. In line with the literature, we find that the Po of RyR1 channels pretreated with rapamycin is significantly higher than that of control channels (Fig. 7, C and D). Of importance, however, we find that addition of FKBP12 does not reduce Po values back to control levels (see second trace and Fig. 7D) suggesting that the rapamycin-induced elevation of Po was not related to dissociation of FKBP12. The rapamycin-induced increase in Po was not caused by nonspecific damage to the channels because lowering cytosolic [Ca²⁺] to subactivating levels (third trace) completely closed the channels showing they were still sensitive to Ca²⁺. A rapamycin-induced increase in cardiac RyR2 Po has also been used to infer that dissociation of FKBP12.6 increases RyR2 Po (11) so we performed similar experiments with RyR2 (see Fig. S4). As with RyR1, we found that rapamycin increased RyR2 activity, although the effect was more marked. Washout of rapamycin did not lower Po, nor did the addition of FKBP12.6, although the channels retained sensitivity to cytosolic Ca²⁺ and were closed by reducing [Ca²⁺]. Because rapamycin does not fully dissociate FKBP12 from RyR1 and because it irreversibly alters RyR1 and RyR2 channel gating, these experiments highlight the need to use native RyR channels that have not been chemically treated to probe the functional effects of FKBP12/FKBP12.6. DISCUSSION To our knowledge, a novel and unexpected finding of this study is that FKBP12.6 is a potent activator of the rabbit skeletal RyR1, whereas FKBP12 is an inhibitor. The results contrast with the situation in cardiac muscle where FKBP12 is an activator of RyR2 and FKBP12.6 is an antagonist of FKBP12 (15) but does not, itself, lower Po. We performed site-directed mutagenesis of the FKBP12 molecule and found that the selective ability of FKBP12 to activate RyR2 and inhibit RyR1 is contained within the three amino acid residues; Glu31, Asp32, and Trp59. Mutation of these key residues to those found in FKBP12.6, caused a complete switch from FKBP12-like action to FKBP12.6-like action. Experiments where sequential addition of FKBP12 and FKBP12.6 are made to the cytosolic face of RyR channels indicate that these proteins would compete for the same binding sites on RyR1 and RyR2. This is not surprising in view of the structural similarity of FKBP12 and FKBP12.6 but also in the light of cryo-electron microscopy and single-particle three-dimensional reconstruction studies indicating that FKBPs bind within similar binding pockets on RyR1 and RyR2 (37–39). Use of fluorescence resonance energy transfer also suggests that FKBP12 and FKBP12.6 would bind in the same locations on RyR1 and RyR2 and with similar orientation (40). We show that FKBP12 and FKBP12.6 exert different effects on the gating of both RyR1 and RyR2. This indicates that the binding sites on the RyR1 and RyR2 channel proteins could be composed of different amino acid residues. Confirmation of this idea comes from binding studies (12,28) using radiolabeled FKBP12/12.6, which indicate that canine cardiac and rabbit skeletal RyR have different affinity for FKBP12/12.6 (although it should be remembered that subsequent work demonstrated that canine RyR2 has unusually high affinity for FKBP12.6 that is not shared by other mammalian RyR2 isoforms (41)). Another explanation for the different functional effects of FKBP12/12.6 could be that the binding interactions between FKBPs/RyR1 and FKBPs/RyR2 produce different changes in channel gating simply because of subtle differences in RyR1 and RyR2 channel gating mechanisms. For example, RyR1 and RyR2 are regulated slightly differently by cytosolic Ca²⁺, especially at inactivating [Ca²⁺] (42–44), and there are subtle differences in the mechanisms by which other ligands such as ATP, caffeine, or suramin activate RyR1 and RyR2 (45–48). We show that activation of RyR1 by FKBP12.6 involves an increase in the frequency of channel opening. This is similar to the mechanism by which cytosolic Ca²⁺ activates RyR1 (49) and therefore FKBP12.6 may be sensitizing the channel to cytosolic Ca²⁺. We have previously demonstrated that FKBP12 sensitizes RyR2 to cytosolic Ca²⁺ (15) and therefore this may be a common mechanism by which FKBPs regulate RyR channels. We cannot be so confident about the mechanism by which FKBP12 inhibits RyR1; it may reduce RyR1 sensitivity to cytosolic Ca²⁺ but because Po is lowered so much, we cannot collect enough opening events for lifetime analysis. The important, take-home message, though, is that FKBP12 and FKBP12.6 drive Po in opposite directions for both RyR1 and RyR2. This has important consequences for skeletal muscle function if the relative ability of FKBP12 and FKBP12.6 to bind to RyR1 is affected in stress, exercise, aging, or disease. Although we and others have previously reported that FKBP12.6 does not, itself, reduce the Po of RyR2 (12,14,28), opinion to the contrary still persists. Our experiments with rapamycin now indicate why this could be. Rapamycin is a frequently used tool for dissociating FKBPs from RyR channels and irreversible increases in RyR Po after rapamycin treatment have led to the conclusion that RyRs must be bound by FKBPs to ensure stable low Po channel gating (11,31,35,50). However, FKBP12 or FKBP12.6 was not added back in the bilayer experiments to examine if these proteins could reverse a rapamycin-induced increase in Po. We have now demonstrated that use of rapamycin may produce misleading results because it can irreversibly increase RyR Po in a manner that is independent of the presence or absence of FKBPs. FK506 is another drug, used extensively to dissociate FKBPs from RyRs. However, studies conducted on intact skeletal fibers have also shown effects of both rapamycin and FK506 on excitation-contraction coupling that are unrelated to the removal of FKBPs (51,52).1,8-Diaminooctane Purity & Documentation Again, incorrect conclusions could be drawn from using this compound if it was not completely removed during a subsequent experiment.PMID:34902646 Another problem is that [³H]ryanodine binding has often been used to indicate RyR channel activity following rapamycin treatment rather than examining the detailed single-channel behavior of RyR1/RyR2 channels directly following incorporation into bilayers. [³H]ryanodine binding can provide an incorrect approximation of the effect of an intervention on RyR activity if that intervention also directly affects the binding of ryanodine. For example, calmodulin increases RyR2 Po but decreases [³H]ryanodine binding because calmodulin also reduces the rate of association of ryanodine to RyR2 (53). There is no study that has investigated whether FKBPs could directly alter the rate of association or dissociation of ryanodine to RyRs or, particularly pertinent to this study, whether rapamycin itself influences ryanodine binding independently of Po. It is very relevant that a single-channel report by Ahern et al. (1997) (33) suggests that ryanodine modification of RyR1 may be reversible after treatment with FK506. Any such increase in the rate of dissociation of ryanodine from RyR channels would, naturally, affect the binding of [³H]ryanodine to cardiac or skeletal SR. We (and others (34,35)) have also shown that rapamycin-treated skeletal SR vesicles will still have residual FKBP12 molecules associated (even if below immunodetection levels) and this will be a significant confounding factor given the very high affinity of FKBPs for RyR channels. Endogenous FKBPs will be present within the incubation medium for the [³H]ryanodine binding assay and will already be bound to an unquantified number of RyR channels. Using [³H]ryanodine binding to skeletal SR vesicles to assay the functional actions of FKBPs will therefore provide results that are difficult to interpret.

Our mutant experiments have begun to distinguish those regions of the FKBP proteins that are important for efficacy. The FKBP12 mutant, FKBP12E31Q/D32N/W59F, clearly has efficacy as an activator of RyR1 but appears to have no or low efficacy as a regulator of RyR2. Our experiments do not provide accurate measurement of the affinity of FKBP12E31Q/D32N/W59F for RyR1 or RyR2, however, they suggest that FKBP12E31Q/D32N/W59F retains high affinity for both RyR1 and RyR2 because the effects of adding FKBP12E31Q/D32N/W59F to the cytosolic chamber are irreversible after washout (see Fig. 6, A and C), and preaddition of FKBP12E31Q/D32N/W59F prevents FKBP12 from activating RyR2 (data not shown). Indeed, this same triple FKBP12 mutant has previously been shown to be capable of displacing ³⁵S-labeled FKBPs bound to skeletal and cardiac SR vesicles indicating that high affinity binding to RyR1 and RyR2 is retained (29). The FKBP12 single point mutants E31Q, D32N, and W59F also bind tightly to rabbit skeletal RyR1 as evidenced by coimmunoprecipitation of GST-mutant FKBP12 and RyR1 (20). Crystallographic data show that Trp59 in FKBP12 and Phe59 in FKBP12.6 are located within the rapamycin hydrophobic binding pocket. This region is also suggested to provide the hydrophobic cavity involved in binding RyR channels (37,38,54,55). Mutations at position 59 in FKBP12/FKBP12.6 clearly do not abolish the binding of FKBPs to RyRs (20,29), although some change in affinity is indicated (29). The larger amino acid in FKBP12 does not alter the fold of the protein but it could influence the particular interactions between FKBPs and RyR2 that lead to changes in channel gating. The residues in position 31 and 32 point away from the hydrophobic core of the proteins, and there are no structural differences between FKBP12 and FKBP12.6 in this region, however these residues could be relevant for electrostatic reasons, as FKBP12 carries two negative charges very close to each other, which are not present in FKBP12.6. A recent publication (39) suggests involvement of electrostatic charges in the interactions between FKBP12 and RyR1 and the formation of a salt bridge between Asp32 on FKBP12 and Arg976 on RyR1, which stabilizes the binding. If this hypothesis is correct, the mutations E31Q and D32N (where two negative charges in FKBP12 are substituted by the corresponding neutral residues of FKBP12.6), could lead to a critical change in protein function as these residues may be crucial for producing the precise binding interactions that enable FKBP12 to inhibit RyR1 and activate RyR2.

Physiological and pathophysiological perspectives
Our study calls for a fresh evaluation of the roles of FKBPs in cardiac and skeletal muscle and, in fact, in all tissues where RyR1 or RyR2 are present. It has generally been assumed that FKBP12 is the only relevant physiological regulator of RyR1, whereas FKBP12.6 is the only important isoform that influences the function of cardiac muscle and other tissues where RyR2 is expressed. Because our experiments clearly demonstrate that both isoforms of FKBP can modulate both isoforms of RyR at extremely low concentrations, and since both FKBP12 and FKBP12.6 are present in skeletal and cardiac cells (12,27,28), SR Ca²⁺-release in cardiac and skeletal muscle may depend on the competitive, dual regulation by both FKBP12 and FKBP12.6. The literature reports levels of 1–3 mM FKBP12 in cardiac and skeletal muscle but much lower (100–200 nM (56)) or undetectable (12,27,28) levels of FKBP12.6. Regarding RyR2, it now appears that canine RyR2 is somewhat of an outlier in having particularly high affinity for FKBP12.6 (41). For all other species of RyR2 investigated, RyR2 appears to also have high affinity for FKBP12 (15,41). In sheep, mass spectrometry demonstrated that FKBP12 can be detected in membrane fractions containing RyR2 with high confidence, whereas FKBP12.6 can only be detected with low confidence (15). Recent immunoblot analysis also showed that FKBP12 is present in cardiac cells (and in membrane fractions containing RyR2) of three mammalian species (pig, rabbit, mouse) at much higher levels than FKBP12.6 (34). In skeletal muscle, there is evidence that FKBP12 is more likely to be associated with RyR1 than FKBP12.6 (34,57). However, because FKBP12.6 is present in skeletal muscle and because we show a functional effect of FKBP12.6 at very low concentrations, we conclude that FKBP12.6 may also play a role in regulating RyR1 in skeletal muscle. It is clear that the relative level of expression of FKBP12 and FKBP12.6 is important. In this regard, it is notable that FKBP binding to RyRs has been reported to be reduced in certain skeletal muscle pathologies (2,3,5). This may reflect an altered ratio in the expression levels of FKBP12 and FKBP12.6 or could be due to changes to RyR1 that affect its relative affinity for FKBP12/FKBP12.6. For example, a reduction in RyR1/FKBP12 binding as reported for dystrophic muscle (5) and sarcopenia (58,59), would be expected to lead to increased RyR1 Po due to dissociation of FKBP12 (which reduces RyR1 Po) and the possible increased binding by FKBP12.6 (which increases RyR1 Po). Fig. 8 suggests how the dual regulation of SR Ca²⁺-release by FKBP12 and FKBP12.6 may operate in skeletal muscle under physiological and pathophysiological conditions. Our study has clear implications for other tissues where both RyRs and FKBPs are expressed. We should not assume that FKBP12 will exclusively bind to RyR1 or that FKBP12.6 will only bind to RyR2, rather, that both proteins can interact with either RyR isoform and that the absolute binding stoichiometry may vary from tissue to tissue. There are many reports indicating that FKBPs play an important role in intracellular Ca²⁺ release in a wide range of different tissues and cell types. These include bladder smooth muscle (60), pancreatic β-cells (61), vascular smooth muscle (62), endothelial cells (63), and various neuronal cells (64). Changes to the relative FKBP12/FKBP12.6 expression level in these cells may have important pathological implications.

CONCLUSION
We have shown that RyR1 is activated by FKBP12.6 but inhibited by FKBP12 and use of the FKBP12E31Q/D32N/W59F mutant demonstrates that efficacy is controlled by very small changes in FKBP structure. The experiments highlight the need to understand the functional consequences of FKBP12/FKBP12.6 binding to RyR channels at the single-channel level to recognize the putative physiological roles of FKBP/RyR interactions in different cell types and the changes that occur in disease and aging.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com

The generation of defined neuronal subtypes from pluripotent stem cells remains a cornerstone in regenerative neuroscience. This study reports the development of a scalable, reproducible protocol to differentiate mouse embryonic stem cells (mESCs) into V2a interneurons—a key excitatory component of spinal and hindbrain central pattern generators. The approach leverages a 2⁻/4⁺ induction strategy, where mESCs are first aggregated into embryoid bodies (EBs) in suspension, then plated onto gelatin-coated surfaces with controlled exposure to retinoic acid (RA) and purmorphamine (Pur), a mild sonic hedgehog (Shh) agonist. Systematic variation of RA (10 nM–10 mM) and Pur (10 nM–1.5 mM) concentrations revealed that low RA combined with high Pur maximized expression of V2a-specific transcription factors including Chx10, Lhx3, and Hb9. qRT-PCR analysis showed a fourfold increase in Chx10 mRNA at 10 nM RA and 1 mM Pur compared to higher RA conditions. Immunocytochemistry confirmed strong nuclear Chx10 staining in differentiated cultures, with minimal co-expression of markers associated with alternative fates such as photoreceptors (Crx) or motoneurons (Hb9). Notably, the addition of DAPT—an inhibitor of Notch-1 signaling—on day 4 of induction led to a dramatic eightfold enrichment in Chx10⁺ cells, underscoring the role of Notch in suppressing V2a lineage commitment. Flow cytometry quantified this shift, showing a rise from 2.25% to 16.83% Chx10⁺ cells upon DAPT treatment. Furthermore, dissociated cultures displayed robust neurite outgrowth and co-expression of β-tubulin III, confirming neuronal identity. The protocol was validated across three independent biological replicates with consistent outcomes. These results establish a highly efficient method for producing large-scale populations of V2a-like interneurons, suitable for high-throughput screening, disease modeling, and functional studies. By integrating precise modulation of RA, Shh, and Notch pathways, this protocol provides a powerful tool for dissecting the molecular mechanisms underlying V2a interneuron specification and offers a foundation for future translation into human pluripotent stem cell systems.

—

**Molecular Mechanisms Underlying V2a Interneuron Specification in Differentiating mESCs**

Understanding the molecular basis of V2a interneuron fate determination is essential for advancing regenerative medicine and developmental neurobiology. In this study, we systematically analyzed the transcriptional regulation driving V2a interneuron formation from mouse embryonic stem cells (mESCs). Using a 2⁻/4⁺ differentiation protocol, we modulated two key signaling pathways: retinoic acid (RA), which influences rostral-caudal patterning, and sonic hedgehog (Shh), which controls dorsoventral axis formation. qRT-PCR data demonstrated that increasing Pur concentration up to 1 mM significantly enhanced expression of V2a-associated genes such as Chx10, Lhx3, and Foxn4, while higher doses (1.5 mM Pur or 0.6 mM SAG) suppressed Chx10, suggesting a narrow therapeutic window for Shh activation.PDLLA3000-mPEG2000, PDI≤1.25 Biological Activity Conversely, decreasing RA levels—from 2 mM down to 10 nM—resulted in a progressive increase in Chx10 expression, indicating that lower RA favors more rostral identities characteristic of V2a interneurons located in the hindbrain respiratory centers. Analysis of Hox gene expression confirmed this positional shift: Hoxc8 (caudal marker) increased with RA, whereas Hoxc5 (rostral marker) remained stable, supporting retention of cervical/hindbrain identity. Critically, Crx expression—the photoreceptor progenitor marker—was consistently suppressed across all RA and Pur conditions, ruling out unintended retinal differentiation. Notch inhibition via DAPT led to significant upregulation of Chx10 and downregulation of Gata3, confirming the known antagonistic relationship between Notch signaling and V2a fate. Immunocytochemical validation corroborated these findings, showing clear Chx10 protein expression and absence of off-target markers. Moreover, Chx10⁺ cells co-expressed neuronal markers like β-tubulin III and displayed complex morphologies indicative of maturation. Together, these data reveal that V2a interneuron specification is governed by a balance between RA-mediated positional cues and Shh/Notch-regulated lineage decisions. This work provides a comprehensive molecular map of V2a differentiation, offering insights into how extrinsic signals converge on intrinsic transcriptional networks to determine neuronal identity.

—

**Translational Potential of an mESC-Derived V2a Interneuron Model for Neurological Research**

The ability to generate functionally relevant neuronal subtypes from stem cells holds transformative potential for neurological research and therapy. This study demonstrates the feasibility of deriving V2a interneurons—critical regulators of locomotion, reaching, and respiration—from mouse embryonic stem cells (mESCs) using a defined, chemically optimized protocol.Olutasidenib In Vitro By combining low retinoic acid (RA), high purmorphamine (Pur), and Notch inhibition with DAPT, we achieved efficient and selective differentiation into Chx10⁺ interneurons, with flow cytometry confirming a nearly eightfold increase in yield compared to control conditions.PMID:35211144 These cells exhibited mature neuronal morphology, expressed pan-neuronal markers such as β-tubulin III, and showed early signs of glutamatergic identity through Vglut immunoreactivity. Importantly, no evidence of off-target differentiation into photoreceptors (Crx-negative) or motoneurons (low Hb9) was observed, highlighting the specificity of the protocol. The scalability and reproducibility of the method make it ideal for high-content screening, drug discovery, and mechanistic studies of CPG circuitry. Furthermore, the protocol’s reliance on well-characterized signaling molecules suggests compatibility with human pluripotent stem cells. Existing protocols for motor neuron derivation from human ESCs share similar foundational steps, implying that this V2a-specific approach could be adapted for human applications. Future work will focus on long-term culture, electrophysiological characterization, and integration into spinal cord tissue models to assess functional connectivity. Ultimately, this model system not only advances our understanding of V2a interneuron development but also opens new avenues for treating spinal cord injuries, respiratory disorders, and other conditions involving disrupted central pattern generation. Its translational readiness positions it as a pivotal tool in the next generation of stem cell-based therapies.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com

The analysis of splicing patterns in the primary HIV-1 subtype B isolate P2149-3 has revealed unprecedented complexity in RNA processing, highlighting previously unrecognized mechanisms that may shape viral gene expression and pathogenesis. Through RT-PCR followed by nested amplification and automated size quantification using fluorescently labeled primers, we identified a series of doubly spliced (DS) transcripts with sizes inconsistent with known splice site usage in HIV-1. These anomalies were traced to the activation of two novel 3′ splice sites—A4d and A4h—for Rev RNA generation, as well as the emergence of atypical Nef transcripts.

A4d, located five nucleotides upstream of the canonical A4a site, was found to be the dominant splice site in P2149-3, utilized in over 60% of Rev transcripts across all time points post-infection. This site had only been previously reported in a T cell line-adapted virus (SF2) and a group O isolate (ANT70C), suggesting it is not a common feature of standard HIV-1 replication. The exon composition of A4d-containing transcripts was predominantly 1.4d.7 and 1.3.4d.7, indicating functional coding potential for Rev protein variants. Similarly, A4h, situated 20 nucleotides upstream of A4c, was detected in three distinct Rev isoforms: 1.4h.7, 1.2.4h.7, and 1.3.4h.7. Although less frequently used than A4d, its presence confirms the existence of an additional regulatory layer in Rev mRNA maturation.4,5-Difluorophthalic acid Biological Activity

Beyond Rev, the study uncovered three unusual Nef transcripts. One utilized the 3′ splice site A5a, located just 4 nt downstream of the usual A5 site, and another employed A7a—previously observed only in minor fractions within HXB2. Most striking was the identification of a transcript with exon structure 1.3.7, which involves splicing from D1 to A7, a pattern previously documented only in rare instances through deep sequencing of p89.6 isolates. These findings suggest that alternative splicing in primary HIV-1 isolates can generate a broader repertoire of protein isoforms than previously recognized.

Sequence analysis revealed key genomic features enabling this atypical splicing. For A4d, a strong polypyrimidine tract with nine pyrimidines interspersed with two purines and a branch point sequence identical to NL4-3’s supported efficient recognition. For A4h, although the polypyrimidine tract was suboptimal due to interruptions by purines, the presence of a conserved mammalian branch point consensus (UACAAAU) with five potential base pairings to U2 snRNP likely enhances splicing efficiency. Additionally, the sequence context around A4h in P2149-3 (AAG/G) aligns more closely with the optimal YAG/G consensus than the AAG/U sequences found in other subtype B strains, potentially increasing its competitive advantage.

These results challenge the conventional view of HIV-1 splicing as a highly constrained process governed by a limited set of canonical splice sites.Monomethyl In Vitro Instead, they demonstrate that primary isolates exhibit significant flexibility in splice site selection, possibly driven by subtle differences in local RNA structure and cis-regulatory elements.PMID:35164469 This plasticity may allow the virus to fine-tune protein expression in response to host cellular environments or immune pressure. Moreover, the preferential use of non-canonical sites like A4d and A4h underscores the importance of studying natural infections rather than relying solely on lab-adapted strains.

The discovery of these novel splicing patterns has implications for vaccine design and antiviral therapy. Altered splicing could lead to the production of immunologically distinct protein variants, potentially evading host immune responses. Furthermore, targeting splicing regulation might offer a new avenue for therapeutic intervention. Future research should focus on characterizing the functional properties of these variant proteins, assessing their impact on viral fitness, and evaluating their role in disease progression.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com

The integration of electronic systems into three-dimensional (3D) structures marks a transformative leap in robotics and smart device engineering. Traditional electronics, confined to flat, planar substrates, struggle to conform to the complex geometries inherent in robotic bodies. This limitation has driven the development of 3D electronics—systems where circuits, sensors, and power components are embedded within or shaped around 3D objects, enabling seamless functionality without compromising mechanical performance. The emergence of advanced additive manufacturing techniques, particularly 3D printing, has made this vision not only feasible but increasingly practical.

One of the most significant advantages of 3D electronics is its ability to overcome the spatial constraints imposed by conventional 2D designs. By leveraging multi-material 3D printing, engineers can fabricate entire electronic systems in a single process, including conductive traces, insulating layers, electrodes, and even encapsulation. For example, fused deposition modeling (FDM) printers equipped with dual nozzles can simultaneously deposit conductive filaments—such as carbon-black-polymer composites or silver-loaded thermoplastics—alongside non-conductive polymers to form integrated circuits directly within structural parts. This approach eliminates the need for post-assembly wiring, reduces system weight, and enhances durability under dynamic motion.

A compelling case study involves the fabrication of a 3D-printed gaming die with embedded microcontrollers, accelerometers, and rechargeable lithium-polymer batteries—all housed within the cube’s internal volume. The die features a standard USB port for recharging and wireless communication capabilities, demonstrating how 3D electronics can integrate multiple functionalities into a compact, functional object. Similarly, cylindrical 3D magnetometers have been printed using embedded microprocessors and orthogonal Hall-effect sensors, allowing for precise orientation detection in robotic limbs and drones.CMIT/MIT (2.0-2.5% in water) Protocol

Beyond passive components, active devices such as transistors, capacitors, and antennas have also been successfully fabricated via 3D printing. A notable example is the direct ink writing (DIW) of liquid metal inks like gallium-based alloys into intricate 3D pathways. These flexible conductive structures enable stretchable circuits capable of withstanding repeated deformation—ideal for soft robotics. Furthermore, electroless plating techniques allow copper deposition on 3D-printed polymer scaffolds, forming high-performance inductors and interconnects with excellent conductivity and thermal stability.Dihydrochalcone Amyloid-β

Another breakthrough lies in the use of bio-inspired materials and sustainable inks.PMID:34937949 Researchers have developed cellulose-silver nanowire (AgNW) composites that are both biodegradable and highly conductive, suitable for eco-friendly RF devices and ion-selective sensors. These materials can be printed onto curved surfaces, such as hemispherical insoles, creating wearable health monitors that track pressure distribution and temperature changes during walking or standing.

However, challenges remain. Resolution limitations in current 3D printing technologies hinder the fabrication of ultra-fine features required for high-frequency applications. Surface roughness from layer-by-layer deposition can degrade electrical performance, especially in high-speed signal transmission. Additionally, material compatibility issues—such as thermal mismatch between conductive inks and polymer substrates—can lead to delamination or cracking over time. Advanced post-processing methods, including chemical reduction and thermal sintering, help improve conductivity but must be carefully controlled to avoid damaging sensitive substrates.

Despite these hurdles, the potential of 3D-integrated electronics is undeniable. From self-powered tactile sensors to embedded microfluidic systems in biomedical robots, the technology enables unprecedented levels of miniaturization, customization, and functionality. As printing resolution improves and new printable conductive materials emerge, the line between hardware and structure will continue to blur.

In the context of sensing robots, 3D electronics serve as the nervous system—enabling real-time data acquisition, processing, and feedback control. Whether detecting subtle muscle movements in prosthetics or monitoring environmental toxins in autonomous drones, these embedded systems provide the intelligence needed for adaptive, responsive behavior. With ongoing advancements in materials science and manufacturing precision, 3D electronics are poised to become the foundational architecture of future intelligent machines—where every part is both structure and function.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com

The survival of cells with defective Smc5/6 complexes under replication stress depends on a delicate balance between DNA damage checkpoint signaling and the regulation of homologous recombination (HR) intermediates. While both pathways are essential, their relative contributions differ depending on the duration and intensity of stress. The smc6-P4 mutant exhibits profound sensitivity to methyl methanesulfonate (MMS), characterized by elevated levels of X-shaped recombination intermediates (X-mols) and impaired Rad53 phosphorylation—a hallmark of defective checkpoint activation. Genetic suppression by deletion of the helicase Mph1 has long been attributed to reduced X-mol accumulation. However, our findings reveal that Mph1 also induces persistent Rad53 hyperphosphorylation, indicating a dual role in enhancing checkpoint signaling.

To determine whether checkpoint hyperactivation alone can rescue smc6-P4 viability, we used two independent approaches to bypass the need for endogenous DNA damage signals. First, we introduced the TEL1-hy909 allele, which confers constitutive Tel1 kinase activity. This resulted in strong Rad53 phosphorylation in smc6-P4 cells without reducing X-mol levels. Second, we engineered an inducible system where Ddc1 and Ddc2 were fused to LacI-GFP modules and targeted to chromosomal LacO arrays. Upon galactose induction, forced proximity of these sensor proteins activated the Mec1 checkpoint even in the absence of DNA lesions, leading to sustained Rad53 phosphorylation. Both interventions restored checkpoint function in smc6-P4 cells and significantly improved survival following transient MMS exposure—mirroring the effect of mph1 deletion.

Despite this improvement, neither strategy conferred resistance to chronic MMS stress. In contrast, mph1 deletion robustly protected smc6-P4 cells under prolonged exposure. This discrepancy suggested that while enhanced checkpoint signaling aids short-term tolerance, it cannot compensate for the underlying defect in HR intermediate resolution. To test this directly, we removed the checkpoint sensor protein Mec3 from smc6-P4 mph1 double mutants. This abolished Rad53 hyperphosphorylation and attenuated checkpoint response, yet mph1 still fully suppressed MMS sensitivity. Furthermore, X-mol levels remained unchanged in these triple mutants, confirming that checkpoint attenuation did not affect HR intermediate turnover. These results indicate that the protective effect of mph1 under chronic stress is primarily due to its ability to reduce recombination intermediates, not checkpoint activation.

Our data support a two-phase model of smc6 mutant survival: during transient replication stress, enhanced checkpoint signaling stabilizes stalled forks and delays cell cycle progression, allowing time for repair and proper segregation.Apixaban impurity 13 In Vitro Under chronic stress, however, persistent HR intermediates become toxic, and their removal becomes the dominant factor for viability.Omeprazole Bacterial Thus, the Smc5/6 complex functions not only in dismantling recombination intermediates but also in modulating checkpoint responses, with these roles being separable.PMID:34808126 This functional distinction may extend to other HR-related mutants such as sgs1 and esc2, which similarly accumulate X-mols and exhibit checkpoint defects. By decoupling checkpoint activation from HR regulation, our study provides a framework for understanding how cells prioritize different mechanisms of genome stability maintenance under varying stress conditions.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com

Retinal ganglion cells (RGCs) are the primary output neurons of the retina, transmitting visual information to the brain via the optic nerve. Their proper development and long-term survival depend on a complex network of transcription factors, among which Pou4f1 and Pou4f2 play pivotal roles. These two closely related POU-domain transcription factors are expressed early in RGC lineage commitment and are essential for specifying RGC identity, guiding axon pathfinding, and ensuring cell survival during embryogenesis. However, their functional relevance in mature RGCs remains controversial. Recent studies have demonstrated that while both genes are critical during development, their deletion in adult mice does not significantly impact RGC survival or function under normal conditions.

To investigate this phenomenon, conditional knockout mouse models were developed using CreER-mediated recombination to delete Pou4f1 and Pou4f2 specifically in adult retinas after tamoxifen induction. Efficient gene ablation was confirmed at two weeks post-treatment through immunostaining with anti-POU4F1 and anti-POU4F2 antibodies. In single knockout mice (Pou4f1CKO or Pou4f2CKO), residual expression was minimal, and in double knockout (DoubleCKO) animals, nearly complete loss of both proteins was observed. Despite this, no significant reduction in total RGC numbers was detected across multiple time points—up to six months after tamoxifen administration. Quantitative analysis of TUJ1+ and ISL1+ RGCs in flat-mounted retinas showed consistent counts between mutant and control groups, indicating that adult RGCs can maintain viability without either factor.

Further investigation revealed that non-RGC retinal cell populations—including amacrine, bipolar, horizontal cells, and Müller glial cells—remained unaffected by Pou4f1 or Pou4f2 deletion. Immunolabeling for markers such as PAX6, CHX10, calbindin, and cyclin D3 showed no changes in cell density or distribution. Additionally, dendritic stratification patterns of amacrine subtypes, assessed by calretinin and CHAT staining, were preserved in the inner plexiform layer, suggesting intact synaptic organization. This specificity confirms that the effects of gene deletion are confined to RGCs and do not result from secondary damage to surrounding retinal structures.

In response to injury, the role of Pou4f1 and Pou4f2 was further evaluated using the controlled optic nerve crush (CONC) model. At three days post-injury, DoubleCKO mice exhibited a transient delay in RGC apoptosis compared to controls, as evidenced by reduced levels of activated caspase-3 in the ganglion cell layer. However, by five days post-crush, the difference in apoptotic cell counts disappeared, and the rate of cell death in both groups converged. This indicates that the absence of Pou4f1 and Pou4f2 does not confer lasting protection against axonal injury-induced degeneration.

These findings suggest that Pou4f1 and Pou4f2 are not required for the maintenance of adult RGCs but may contribute to acute stress responses. Their developmental importance is underscored by earlier studies showing that Pou4f2 knockout results in up to 80% RGC loss and severe axonal misrouting, while Pou4f1 deficiency alters dendritic stratification and disrupts RGC subtype specification. The fact that adult RGCs survive despite the absence of these factors implies the existence of compensatory mechanisms.Anti-TREM2 Antibody Formula Potential candidates include Pou4f3, which persists in a subset of adult RGCs, and ISL1, another transcription factor co-expressed with Pou4f proteins during development and known to regulate RGC differentiation and survival.Triheptanoin site

Interestingly, the lack of long-term dependence on Pou4f1 and Pou4f2 in mature neurons highlights a fundamental shift in transcriptional regulation between developmental and adult stages.PMID:34942348 During embryogenesis, the coordinated activity of Pou4f family members ensures precise cell fate determination and circuit formation. In contrast, once RGCs reach maturity, alternative regulatory networks may sustain their survival independently of these early determinants.

This study underscores the concept of functional redundancy and stage-specificity in transcription factor networks. While Pou4f1 and Pou4f2 are indispensable for RGC maturation during development, they are dispensable for long-term survival in adulthood. These insights are crucial for understanding neuronal resilience and may inform future strategies aimed at enhancing RGC survival in diseases such as glaucoma, where neuroprotection is a major therapeutic goal. Targeting downstream effectors or alternative pathways may offer more effective approaches than attempting to restore the function of developmental transcription factors in mature neurons.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com

6-Hydroxydopamine (6-OHDA) is a potent neurotoxin used to model Parkinson’s disease (PD) due to its selective toxicity toward dopaminergic neurons. While it is well established that 6-OHDA induces oxidative stress and neuronal death, the precise sequence of early axonal events remains poorly understood. This study leverages a microfluidic platform to isolate axons from cell bodies in murine mesencephalic cultures, enabling real-time analysis of axonal transport dynamics following 6-OHDA exposure.

We observed that 6-OHDA rapidly disrupts mitochondrial movement within 30 minutes, with a significant reduction in both the number of motile mitochondria and their velocity in both anterograde and retrograde directions. This effect was not restricted to dopaminergic neurons—non-dopaminergic axons exhibited comparable transport deficits—indicating a non-selective impact on axonal trafficking machinery.9-cis-Retinoic acid Endogenous Metabolite Concomitantly, mitochondrial membrane potential collapsed, as evidenced by reduced TMRE fluorescence, suggesting functional impairment of mitochondria prior to morphological changes.

Interestingly, mitochondrial size remained unchanged even after one hour of treatment, ruling out fragmentation as an initial cause of transport failure. Instead, the loss of motility appears linked to energy depletion or redox-sensitive disruption of motor proteins. The fact that antioxidants such as NAC and MnTBAP reversed transport defects strongly implicates reactive oxygen species (ROS) in this process.Nup93 Antibody site These findings align with previous reports showing that ROS scavengers protect against 6-OHDA-induced damage, reinforcing the role of oxidative stress in early axonal dysfunction.

Axonal transport of synaptic vesicles, labeled with synaptophysin-cerulean, was also severely impaired within 30 minutes, further underscoring the broad impact of 6-OHDA on cargo trafficking.PMID:34782292 Despite the early onset of transport failure, structural breakdown of microtubules—assessed via acetylated tubulin immunostaining—was not apparent until 6 hours post-treatment. By 24 hours, over 80% of DA and non-DA axons displayed fragmented microtubule tracks, indicating that cytoskeletal disintegration follows rather than precedes transport collapse.

Cell death in the somal compartment was minimal at 24 hours but significantly increased by 48 hours, confirming a retrograde degeneration pattern consistent with in vivo observations. Notably, when toxin was applied only to the axonal compartment, degeneration still progressed to the soma, demonstrating the feasibility of modeling retrograde pathology in vitro using this system.

Autophagy, assessed by LC3-GFP puncta formation, emerged later—around 9 hours after 6-OHDA exposure—suggesting it is a downstream consequence rather than a trigger of transport failure. While autophagosome formation occurred in both DA and non-DA neurons, the response was more pronounced in non-DA neurons, hinting at differential regulation of autophagy in distinct neuronal populations.

In conclusion, our results reveal that 6-OHDA initiates axonal degeneration through rapid, ROS-mediated disruption of mitochondrial and synaptic vesicle transport. This early dysfunction precedes microtubule disassembly and cell death, supporting a “dying-back” mechanism in PD pathogenesis. The delayed activation of autophagy may reflect a failed attempt to clear damaged organelles, leading to prolonged axonal stress. Targeting early transport deficits with antioxidants could represent a viable neuroprotective strategy, offering new insights into therapeutic interventions for Parkinson’s disease.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com

Pulmonary infections caused by Pseudomonas aeruginosa remain a significant clinical challenge, particularly in patients with cystic fibrosis and diffuse panbronchiolitis. This opportunistic pathogen exhibits remarkable resistance to antibiotics and produces multiple virulence factors, including proteases such as elastase (PE), which contribute to tissue damage and systemic infection. PE is known to disrupt epithelial barriers and promote inflammation, but its role in modulating inflammatory responses in lung fibroblasts has not been fully elucidated. This study investigates the molecular mechanism by which PE induces inflammatory signaling in human lung fibroblasts, focusing on the epidermal growth factor receptor (EGFR)/mitogen-activated protein kinase (MAPK) pathway and its downstream effects on interleukin-8 (IL-8) production.

We utilized IMR-90 human lung fibroblasts to examine the effects of PE on intracellular signaling pathways. Treatment with enzymatically active PE led to rapid phosphorylation of EGFR at Tyr1068 and subsequent activation of ERK1/2, a key component of the MAPK cascade. This activation was time- and concentration-dependent, peaking at 10 minutes after exposure. Western blot analysis confirmed that PE-induced ERK1/2 phosphorylation was significantly attenuated by pretreatment with U0126, a specific MEK inhibitor, indicating dependence on the MEK-ERK axis. Furthermore, neutralizing antibodies against EGFR or the tyrosine kinase inhibitor AG1478 effectively blocked both EGFR phosphorylation and downstream ERK activation, demonstrating that PE signals through EGFR to initiate the MAPK pathway.SLC34A2 ProteinBiological Activity

In addition to MAPK activation, PE induced nuclear translocation of NF-κB, a master regulator of proinflammatory gene expression. This was observed within 10 minutes of treatment and persisted for at least one hour. Nuclear fractionation followed by Western blotting revealed increased levels of the p65 subunit of NF-κB in PE-treated cells compared to controls. The involvement of NF-κB in IL-8 regulation was further supported by experiments using BAY 11-7085, a specific NF-κB inhibitor, which significantly reduced PE-induced IL-8 secretion.

To assess functional outcomes, we measured IL-8 mRNA and protein levels using Northern blotting, real-time PCR, and ELISA. PE treatment resulted in a robust increase in IL-8 mRNA expression, reaching peak levels at 2 hours post-exposure and declining thereafter.1,5-Diiodopentane Data Sheet This induction was dose-dependent and critically dependent on EGFR, MEK, and NF-κB activity.PMID:34626678 Pretreatment with inhibitors of any of these components dramatically suppressed both IL-8 gene expression and protein secretion. Notably, heat-inactivated or phosphoramidon-treated PE failed to induce either signaling or IL-8 production, confirming that enzymatic activity is essential.

These findings demonstrate that Pseudomonas aeruginosa elastase activates lung fibroblasts via an EGFR/MAPK/NF-κB signaling cascade, leading to enhanced IL-8 production. This mechanism contributes to the amplification of local inflammation by recruiting neutrophils and exacerbating tissue injury. Given the central role of IL-8 in chronic lung diseases like cystic fibrosis, targeting this pathway may offer therapeutic potential for mitigating inflammation during P. aeruginosa infection.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com

Heart failure remains a significant global health burden, affecting millions and contributing to high morbidity and mortality. The pathophysiology of heart failure involves multiple mechanisms, among which oxidative stress plays a central role. Excessive production of reactive oxygen species (ROS) leads to cellular damage, inflammation, and apoptosis, particularly in cardiomyocytes. This study investigated the protective effects of N-acetylcysteine (NAC), a potent antioxidant, on oxidative stress, nuclear factor kappa B (NF-κB) activation, and cardiomyocyte apoptosis in an experimental model of doxorubicin-induced heart failure in Japanese white rabbits.

A total of 50 rabbits were used, with 10 serving as controls. Heart failure was induced by intravenous administration of doxorubicin at 1 mg/kg twice weekly for eight weeks. Rabbits developing heart failure were divided into two groups: 12 untreated (HF group) and 13 receiving daily oral NAC at 300 mg/kg for four weeks. Echocardiographic and hemodynamic assessments revealed significant impairments in cardiac function in the HF group, including increased left ventricular end-diastolic diameter (LVEDD) and pressure (LVEDP), reduced ejection fraction (EF), and diminished maximal and minimal rates of left ventricular pressure rise (+dp/dtmax and -dp/dtmin).Sugemalimab Formula These parameters improved significantly in the NAC-treated group, indicating enhanced cardiac performance.

Oxidative stress markers were markedly elevated in the HF group. Total antioxidant capacity (tAOC) in serum and myocardium was significantly reduced, while levels of 8-iso-prostaglandin F2 (8-iso-PGF2), a reliable indicator of lipid peroxidation, were substantially increased. Glutathione (GSH) levels were also decreased in the HF group. NAC treatment effectively restored tAOC and GSH levels and significantly reduced 8-iso-PGF2 concentrations, demonstrating its ability to enhance antioxidant defenses and reduce oxidative damage.

Apoptosis was assessed using the TUNEL assay. The apoptotic index was significantly higher in the HF group compared to controls, and this increase was attenuated by NAC treatment. Immunohistochemical analysis showed upregulated expression of pro-apoptotic Bax and downregulated anti-apoptotic Bcl-2 in the HF group, resulting in a decreased Bcl-2/Bax ratio. NAC reversed these changes, promoting cell survival. Western blot analysis confirmed increased NF-κBp65 expression and activity in the HF group, associated with elevated inducible nitric oxide synthase (iNOS) levels and reduced phosphorylation of IκB-α.Ixekizumab Autophagy NAC treatment normalized these protein expressions, suggesting inhibition of NF-κB activation.PMID:34473924

Correlation analyses revealed that myocardial apoptosis was positively correlated with LVEDP, NF-κBp65 expression, and 8-iso-PGF2 levels, but negatively correlated with +dp/dtmax, -dp/dtmin, and the Bcl-2/Bax ratio. These findings highlight the interplay between oxidative stress, inflammatory signaling, and cell death in heart failure progression.

In conclusion, N-acetylcysteine exerts significant cardioprotective effects in a rabbit model of heart failure by reducing oxidative stress, suppressing NF-κB activation, and inhibiting cardiomyocyte apoptosis. These results support the potential therapeutic value of antioxidants like NAC in mitigating structural and functional deterioration in heart failure, although further clinical validation is warranted.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com

Hexavalent chromium [Cr(VI)] is a well-established human carcinogen strongly linked to increased lung cancer risk. Despite extensive epidemiological evidence, the molecular mechanisms underlying Cr(VI)-induced carcinogenesis remain poorly understood due to the absence of reliable in vitro models mimicking chronic exposure. To address this gap, we developed an in vitro transformation model by chronically exposing non-tumorigenic human bronchial epithelial BEAS-2B cells to 1 µM Cr(VI) over 24 weeks. This dose reflects occupational exposure levels and exhibits minimal cytotoxicity. The resulting Cr(VI)-transformed cells (designated BEAS-Cr) displayed hallmark features of malignant transformation: enhanced proliferation, anchorage-independent growth, and tumor formation in nude mice.

Our miRNA microarray analysis revealed a dramatic downregulation of miR-143 in BEAS-Cr cells compared to parental BEAS-2B cells. TaqMan RT-qPCR confirmed a ~35-fold reduction in miR-143 expression. This repression was consistent across multiple independently isolated clones, indicating it is a stable feature of Cr(VI)-induced transformation. Furthermore, miR-143 levels were significantly lower in established lung cancer cell lines (A549, H2195) than in normal BEAS-2B cells, suggesting its potential role as a tumor suppressor in lung carcinogenesis.

To investigate the functional significance of miR-143 repression, we ectopically expressed miR-143 in BEAS-Cr cells. This intervention significantly inhibited their tumorigenic potential both in vitro and in vivo. In tube formation assays using human umbilical vein endothelial cells (HUVECs), conditioned medium from BEAS-Cr cells robustly induced angiogenesis, which was suppressed by miR-143 overexpression. Similarly, in chicken chorioallantoic membrane (CAM) assays, BEAS-Cr cells triggered strong neovascularization, an effect markedly attenuated by miR-143 expression. In a xenograft mouse model, tumors derived from miR-143-overexpressing BEAS-Cr cells were approximately 50% smaller and exhibited a 50% reduction in microvessel density, as assessed by CD31 immunohistochemistry.

Mechanistically, we identified insulin-like growth factor-1 receptor (IGF-IR) and insulin receptor substrate-1 (IRS1) as direct targets of miR-143. Bioinformatics prediction and luciferase reporter assays confirmed that miR-143 binds specifically to the 3′-UTRs of both IGF-IR and IRS1 mRNAs. Overexpression of miR-143 in BEAS-Cr cells reduced IGF-IR and IRS1 protein levels, while knockdown of IGF-IR or IRS1 using siRNAs impaired colony formation and angiogenesis, phenocopying the effects of miR-143 restoration. Critically, forced expression of IGF-IR or IRS1 without their 3′-UTRs reversed the anti-angiogenic effects of miR-143, confirming that these two proteins are key mediators downstream of miR-143.

We further demonstrated that miR-143 represses the ERK signaling pathway via IGF-IR/IRS1. Cr(VI)-transformed cells showed elevated phosphorylation of ERK, which was significantly reduced upon miR-143 overexpression or siRNA-mediated knockdown of IGF-IR/IRS1. This establishes a clear link between miR-143 loss, IGF-IR/IRS1 activation, and ERK hyperactivation in transformed cells.

Finally, we identified interleukin-8 (IL-8) as the primary angiogenic factor upregulated in response to Cr(VI).Benzil web IL-8 mRNA and protein levels were markedly elevated in BEAS-Cr cells. This induction was dependent on IGF-IR/IRS1/ERK signaling, as inhibition of any component suppressed IL-8 expression.Bicalutamide sulfide Biological Activity Recombinant IL-8 potently stimulated HUVEC tube formation, and siRNA-mediated knockdown of IL-8 reduced angiogenesis by 50%.PMID:34710552 Moreover, IL-8 induction was shown to be mediated through hypoxia-inducible factor-1 (HIF-1) and nuclear factor-kappa B (NF-κB), both of which were activated in BEAS-Cr cells and could be suppressed by miR-143 overexpression.

In conclusion, our study establishes a causal and mechanistic link between Cr(VI)-induced miR-143 repression and tumor angiogenesis. The suppression of miR-143 leads to the derepression of IGF-IR and IRS1, resulting in sustained activation of the ERK pathway and subsequent upregulation of IL-8 via HIF-1 and NF-κB. This defines a novel molecular axis—miR-143/IGF-IR/IRS1/ERK/IL-8—that drives the angiogenic switch during Cr(VI)-induced lung carcinogenesis. These findings highlight miR-143 as a potential therapeutic target for preventing or treating Cr(VI)-associated lung cancers.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com